James Crowe Jr. Archives
VUMC antibodies help neutralize two deadly viruses: study
Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
‘DNA’ podcast Season 2 explores COVID, science and trust in communities
Aug. 23, 2021—Listen to Episode 1, Blueprint for a Pandemic-Ready Society, and subscribe on your favorite platform. The first episode of the second season of Vanderbilt University Medical Center’s original podcast series, Vanderbilt Health DNA: Discoveries in Action, tackles bold questions and issues pushed to the surface by COVID-19. This season, the award-winning 10-episode series delves into...
COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study
Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
Team isolates antibodies that target alphaviruses
Aug. 19, 2021—A multi-institutional team led by researchers at Vanderbilt University Medical Center has isolated monoclonal antibodies that in laboratory and animal studies prevented infection by alphaviruses, including the often-lethal Eastern equine encephalitis virus (EEEV).
Study identifies monoclonal antibodies that may neutralize many norovirus variants
Jul. 16, 2021—Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.
Combination antibody therapies should retain effectiveness against emerging COVID-19 variants: study
Jun. 22, 2021—Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature.
Therapeutic antibodies for hantavirus
May. 24, 2021—Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential.
VUMC team’s COVID-19 research featured on “60 Minutes”
Apr. 12, 2021—James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured Sunday on a CBS News 60 Minutes segment titled “The Last Pandemic.”
Crowe receives SEC Faculty Achievement Award
Apr. 12, 2021—James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.
U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC
Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
Novel way to neutralize Rift Valley Fever Virus
Apr. 1, 2021—The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.
Study shows new COVID target could improve vaccines
Apr. 1, 2021—Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.
